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Propylthiouracil (PTU) is a frequently prescribed drug in the treatment of hyperthyroidism. The use of PTU is, however,
accompanied by numerous potentially serious side eﬀects including vasculitis. PTU-related vasculitides can present as haematuria,
pulmonary haemorrhage, or cutaneous lesion together with aspeciﬁc symptoms such as fever, myalgia, arthralgia, and fatigue.
Cerebral involvement is seldom observed. We present a 49-year-old female with Graves’ disease and asthma, who developed
paresis of the proximal extremities, eosinophilia, pulmonary, and cutaneous lesions following treatment with PTU. A cerebral
vasculitis consistent with Churg-Strauss syndrome (CSS) was suspected. Although cerebral involvement is seldom observed with
PTU treatment, cerebral vasculitis should be considered in patients developing CNS symptoms.
Copyright © 2009 R. A. M. Quax et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Numerous observations regarding the detection of a positive
ANCA in patients treated with PTU in Graves’ disease have
been published [1–8]. The determination of antineutrophil
cytoplasmic antibodies (ANCAs) is a highly speciﬁc and
sensitive marker for the so-called ANCA-associated vasculi-
tis. Vasculitis is a disease characterised by an inﬂammatory
reaction in and around blood vessels. The vasculitides are
classiﬁed on the basis of vessel size and the inﬂammatory
reaction pattern. Using indirect immunoﬂuorescence tech-
niques (IFTs), two patterns of staining can be observed.
Antiproteinase 3 (PR3) antibodies produce a diﬀuse cyto-
plasm pattern of staining in the IFT (c-ANCA). The presence
of these antibodies is associated with Wegener’s granu-
lomatosis. A perinuclear pattern of immunoﬂuorescence
staining(p-ANCA)isacharacteristicforthepresenceofanti-
myeloperoxidase antibodies (MPO). These antibodies are
linked with microscopic polyangiitis, but can also be found
in Wegener’s disease and Churg-Strauss syndrome. These
diseases are taken together as ANCA-associated vasculitides.
The exact mechanisms underlying these ANCA-associated
vasculitides are unknown.
PTU-induced ANCA-associated vasculitides mainly
relate to the renal, cutaneous, and pulmonary systems.
We describe apatientwithGraves’hyperthyroidism,who
developed a cerebralvasculitis consistent with Churg-Strauss
syndrome after treatment with propylthiouracil (PTU).
2.CaseReport
In July 2004, a 49-year-old woman was admitted to the
Department of Internal Medicine with complaints of pal-
pitations. Her past medical history was asthma, allergic
diathesis, hay fever, and vitiligo. Laboratory examination
demonstrated an elevated free T4 (30pmol/L) and low
TSH (<0.01mIU/L). Iodine-123 scintigraphyshowed dif-
fuse high uptake indicating Graves’ disease. Treatment
was started with thiamazole (30mg per day). After two
weeks of treatment with thiamazole, the patient devel-
oped a pruritis, and thiamazole was replaced by propy-
lthiouracil (PTU) given in a dose of 100mg three times
a day. Levothyroxine was started at a dose of 87.5µg
daily (block-and-replace therapy). Thereafter, she became
euthyroid.2 International Journal of Rheumatology
Table 1: Criteria for the classiﬁcation of Churg-Strauss syndrome (CSS). The presence of four or more of these criteria yields a sensitivity of
85% and a speciﬁcity of 99.7% for CSS according to the American College of Rheumatology (ACR).
ACR criteria Present in our patient
Asthma Yes
Eosinophilia >10% on diﬀerential white blood cell count Yes
Mononeuropathy or polyneuropathy Yes
Migratory or transient pulmonary opacities detected radiographically Yes
Paranasal sinus abnormalities No
Biopsy containing a blood vessel showing the accumulation of eosinophils in extravascular areas —
Five months after the start of PTU treatment, she
developed a progressive loss of strength in her arms and legs.
Her health deteriorated further with complaints of a painful
abdomen, diarrhoea, and diﬀuse pruritis with skin rashes.
Physicalexaminationuponadmissiontothehospitalshowed
petechiae, neurodermatitis, and nailfold lesions. A mild
paresis of the proximal extremities was observed. Laboratory
tests demonstrated an eosinophilia (4780 eosinophils/µLa n d
44% eosinophils on diﬀerential white blood cell count).
Liver enzymes and creatinine phosphokinase were normal.
Serum creatinine was slightly elevated (111µmol/L) with an
active urine sediment analysis showing traces of protein and
microhematuria.
X-ray examination of the lungs revealed a diﬀuse
interstitial pattern consistent with interstitial pneumonitis.
In the following days, the patient developed fever and
urticaria. Serological investigation revealed the presence
of a positive ANCA with a titre of 1:2048. Anti-MPO
(1:1280) and anti-PR3 (1:640) antibodies were also detected
as measured by ELISA. Screening assays for antinuclear
antibodies (ANAs /ENA/dsDNA) and rheumatoid factors
(anti-CCP) were negative. Other causes for a vasculi-
tis were excluded, like the presence of cryoglobulins or
a hepatitis (screening assays for Hepatitides B and C,
CMV, EBV, and HIV were negative). A systemic vasculitis
was considered most likely. The diﬀerential diagnosis was
of idiopathic hypereosinophilic syndrome, eosinophilia-
myalgia syndrome, or parasitic infection. Although PTU
was stopped immediately, there was progression of the
neurological symptoms. She became totally bedridden due
to progressive loss of strength of the proximal extrem-
ities. She also developed signs consistent with periph-
eral sensory polyneuropathy. The symptoms were more
pronounced on the left side. Furthermore, and so far
unnoticed, she demonstrated a positive Babinski sign on
both sides. Cerebral magnetic resonance imaging revealed
lesions in the parietal regions compatible with recent
infarctions. Other causes of her fever and diarrhoea were
excluded.
Under suspicion of a generalised vasculitis with cere-
bral extension, the patient was treated with methylpred-
nisolone (1000mg/d) for three days, and cyclophosphamide
(15mg/kg iv.) was started at four weeks time intervals.
After 3 days, the methylprednisolone was changed in
prednisolone (1mg/kg/d). Under this treatment regime,
neurological symptoms diminished rapidly, and the clinical
signs of vasculitis including the nailfold lesions, skin rash,
urticaria, and pruritis disappeared. Three weeks after onset
oftreatment,theANCAtitrewasdecreasedto1:1024.Atthat
moment, laboratory values were all normalised. The ANCA
titrefurtherdecreasedto1:64afterthreemonthsandbecame
negative after 1 year until now.
We classiﬁed our patient as Churg-Strauss syndrome
with cerebral involvement induced by the use of propylth-
iouracil (see Table 1).
Two years after initial presentation, she is in clinical good
condition using 7.5mg prednisone and 150mg azathioprine
daily.
3. Discussion
The development of ANCA following treatment with
antithyroid medication has been described numerous times.
In a large cross-sectional study [2]( n = 407), a high
prevalenceofapositiveANCAwasdescribedinpatientswith
Graves’ disease using antithyroid drugs as compared with
euthyroid controls. In patients with Hashimoto’s disease,
there was no signiﬁcant higher prevalence of ANCA. More-
over, the development of a positive ANCA was associated
with propylthiouracil usage to a greater extent than with
carbimazole, highlighting that the autoimmune disease itself
is not (fully) responsible for the development of ANCA. In
a small cross-sectional study [3]( n = 30), 27% of patients
on long-term antithyroid medication were ANCA positive.
These results were also conﬁrmed in another retrospective
study [4]; anti-MPO antibodies were detected in 25% of the
patientstreatedwithPTU,butonly3%ofthepatientstreated
with thiamazole. Data about the prevalence of a positive
ANCA in patients with hyperthyroidism before the start
of the treatment are scarce. In two of these studies [5, 6],
the close relationship between the treatment with PTU and
development of ANCA could be established. No correlation
w a sd e t e c t e db e t w e e nt r e a t m e n tw i t hm e t h i m a z o l ea n d
ANCA positivity. A positive ANCA could only be demon-
strated in the PTU treated patients. In children with Graves’
disease, anti-MPO antibodies were found in 7% of patients
before treatment. Of those patients treated with PTU, 64%
developed anti-MPO antibodies (mean duration of PTU
treatment 4.0 ± 3.6 yr) while none of the patients treated
with thiamazole developed autoantibodies [7]. These cited
observations strongly suggest that antithyroid treatment,
speciﬁcally PTU, is associated with the development of
ANCA.International Journal of Rheumatology 3
Table 2: Most frequent observed clinical symptoms in PTU-
induced ANCA-associated vasculitis. In total, 61 well-described
patients were studied.
Syndrome Frequency Percentage (%)
Renal involvement 44 72
Fever 26 43
Arthralgia 22 36
Pulmonary involvement 16 26
Cutaneous lesions 14 23
Myalgia 11 18
Eye involvement 7 11
Pericardial eﬀusion 2 3
Central nervous system 1 2
However,animportantquestiontosolveiswhetherevery
patient who develops these kinds of antibodies will also
develop an ANCA associated vasculitis.
Most of the literature concerning PTU-induced ANCA-
associated vasculitides has been published as case reports.
After the ﬁrst publication by Dolman et al. [8] in 1993,
numerous case reports of PTU-induced vasculitis have been
described, with a wide spectrum of clinical presentation (see
Table 2).
Renalinvolvementismostlycharacterisedbyhaematuria,
proteinuria, or oliguria [9–25]. Renal biopsies showed
two patterns, either pauci-immune necrotizing glomeru-
lonephritis or pauci-immune crescentic glomerulonephritis.
Skin involvement as a cutaneous ANCA-associated vas-
culitis has been reported several times, with clinical signs as
purpura,ulceratingskin,anderythematouslesions[8,11,14,
15, 18, 22, 26–30]. Skin biopsy mostly revealed the picture of
al e u c o c y t o c l a s t i cv a s c u l i t i s[ 27, 28].
Pulmonary involvement is highly prevalent, although
only one case was proven histologically [10]. In two
other reports, lung biopsy only conﬁrmed the presence
of hemosiderin ﬁlled macrophages [20, 31]. Nevertheless,
as dyspnoea, haemoptysis, or respiratory failure clearly
improved on withdrawal of PTU or were directly correlated
with histological proven vasculitis elsewhere, these clinical
features are strongly indicative of pulmonary vasculitis [9,
10, 13, 17, 20–23, 25, 26, 31]. Other frequently observed
symptoms are arthralgia, fever, myalgia, and scleritis.
To our knowledge, no literature is known about the use
of antithyroid drugs and development of CSS. Even more so,
the presence of eosinophilia is never mentioned in previous
reports.
Recently, the ﬁrst patient with a cerebral vasculitis
following PTU treatment was described [1]. In contrast with
our case report, this patient was only MPO-ANCA positive.
Our patient developed central nervous system symptoms
after using PTU for six months (versus 3 years in the
other patient). The neurological symptoms of our patient
consisted of a progressive loss of muscle strength, positive
Babinski signs, and a sensory polyneuropathy, whereas the
neurological symptoms of the other patient consisted of
cognitive deﬁcits. Signs of recent cerebral infarction were
present in our patient. In both patients, the outcome
improved after discontinuation of the PTU and the start of
immunosuppressive therapy.
Despite accumulating reports demonstrating ANCA-
associated vasculitis following treatment with antithyroid
drugs, most ANCA-positive patients do not have clinical
manifestations of vasculitis [2–7]. This discrepancy suggests
that other factors are of importance in the development of
vasculitis besides ANCA positivity.
Patients developing PTU-induced ANCA-associated vas-
culitis have been shown to have a signiﬁcant higher titre and
aﬃnity of anti-MPO antibodies as compared with ANCA-
positive patients without developing vasculitis [21]. Gao
and coworkers found signiﬁcantly decreased aﬃnity and/or
titre of anti-MPO antibodies after cessation of PTU and
initiation of immunosuppressive therapy in patients with
PTU-induced ANCA-associated vasculitis [22, 32]. There-
fore, the titre and aﬃnity of anti-MPO antibodies might
be clinical markers for the development of PTU-induced
ANCA-associated vasculitis.Further research is needed to
establish this association.
4. Conclusion
Antithyroid drugs, especially PTU, are associated with the
development of ANCA. Not every patient developing ANCA
will develop a vasculitis, given the discrepancy between the
prevalence of PTU-induced ANCA and clinically evident
vasculitis. Consequently, screening of patients using PTU is
not recommended. Further research is needed to asses if titre
and aﬃnity of anti-MPO antibodies can be used to predict
the risk of developing vasculitis following treatment with
antithyroiddrugs.Patientsusingantithyroiddrugsingeneral
and PTU in particular should be closely monitored for signs
of vasculitis, including central nervous system symptoms.
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